CY1120439T1 - Διλειτουργικα πολυπεπτιδια - Google Patents

Διλειτουργικα πολυπεπτιδια

Info

Publication number
CY1120439T1
CY1120439T1 CY20181100507T CY181100507T CY1120439T1 CY 1120439 T1 CY1120439 T1 CY 1120439T1 CY 20181100507 T CY20181100507 T CY 20181100507T CY 181100507 T CY181100507 T CY 181100507T CY 1120439 T1 CY1120439 T1 CY 1120439T1
Authority
CY
Cyprus
Prior art keywords
polypeptides
business interface
peptide
antibody
immune effector
Prior art date
Application number
CY20181100507T
Other languages
English (en)
Inventor
Bent Karsten Jakobsen
Annelise Brigitte Vuidepot
Yi Li
Original Assignee
Immunocore Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120439(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunocore Ltd. filed Critical Immunocore Ltd.
Publication of CY1120439T1 publication Critical patent/CY1120439T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Διλειτουργικό πολυπεπτίδιο το οποίο αποτελείται από έναν ειδικό εταίρο πρόσδεσης για έναν επίτοπο πεπτιδίου-MHC, όπως ένα αντίσωμα ή ένας υποδοχέας Τ κυττάρων ("TCR"), και έναν άνοσο τελεστή, όπως ένα αντίσωμα ή μια κυτοκίνη, με το τμήμα άνοσου τελεστή να συνδέεται στο Ν-άκρο του τμήματος πρόσδεσης πεπτιδίου-MHC.
CY20181100507T 2009-05-20 2018-05-04 Διλειτουργικα πολυπεπτιδια CY1120439T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0908613.3A GB0908613D0 (en) 2009-05-20 2009-05-20 T Cell Reseptors
EP10720803.5A EP2432802B1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides

Publications (1)

Publication Number Publication Date
CY1120439T1 true CY1120439T1 (el) 2019-07-10

Family

ID=40834242

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161101365T CY1118405T1 (el) 2009-05-20 2016-12-30 Διλειτουργικα πολυπεπτιδια
CY20181100507T CY1120439T1 (el) 2009-05-20 2018-05-04 Διλειτουργικα πολυπεπτιδια
CY20191100410T CY1121558T1 (el) 2009-05-20 2019-04-12 Διλειτουργικα πολυπεπτιδια

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161101365T CY1118405T1 (el) 2009-05-20 2016-12-30 Διλειτουργικα πολυπεπτιδια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100410T CY1121558T1 (el) 2009-05-20 2019-04-12 Διλειτουργικα πολυπεπτιδια

Country Status (21)

Country Link
US (6) US10130721B2 (el)
EP (3) EP3112377B1 (el)
JP (4) JP5667171B2 (el)
CN (1) CN102439034B (el)
AU (1) AU2010250951B2 (el)
BR (1) BRPI1013029A2 (el)
CA (2) CA2762604C (el)
CY (3) CY1118405T1 (el)
DK (3) DK3112376T3 (el)
EA (1) EA020841B1 (el)
ES (3) ES2608653T3 (el)
GB (1) GB0908613D0 (el)
HR (3) HRP20170086T1 (el)
HU (3) HUE032929T2 (el)
LT (3) LT3112377T (el)
MX (1) MX340168B (el)
PL (3) PL2432802T3 (el)
PT (3) PT2432802T (el)
SI (3) SI3112376T1 (el)
TR (2) TR201905437T4 (el)
WO (1) WO2010133828A1 (el)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
CN103974974A (zh) 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
AU2012316859A1 (en) * 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
EP2773670A4 (en) 2011-11-03 2015-09-02 Tolera Therapeutics Inc ANTIBODIES AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES
WO2013105856A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
EP3116901B1 (en) 2014-03-14 2019-06-12 Immunocore Limited Tcr libraries
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016070814A1 (zh) 2014-11-07 2016-05-12 广州市香雪制药股份有限公司 一种可溶的异质二聚t细胞受体及其制法和应用
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
DK3430037T3 (da) * 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
KR102473964B1 (ko) 2016-04-08 2022-12-06 이뮤노코어 리미티드 T 세포 수용체
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
CA3025894A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
EP3532078A4 (en) * 2016-10-31 2020-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. ARTIFICIAL ANTIGEN PRESENT CELLS USED FOR THE EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
EP3535288A1 (en) 2016-11-07 2019-09-11 Immunocore Limited Peptides
CN108203459A (zh) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 源自于prame的肿瘤抗原短肽
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
JP2021522835A (ja) 2018-05-14 2021-09-02 イムノコア リミテッド 二機能性結合ポリペプチド
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
CN113164626A (zh) * 2019-01-14 2021-07-23 南京传奇生物科技有限公司 嵌合受体多肽及其用途
CA3126611A1 (en) 2019-01-17 2020-07-23 Immunocore Limited Formulations of soluble t cell receptor(tcr) and single chain fragment variable (scfv) bispecific proteins
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
JP2022519649A (ja) 2019-02-08 2022-03-24 ジェネンテック， インコーポレイテッド がんの診断および治療方法
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
US20220152109A1 (en) 2019-03-18 2022-05-19 Ludwig Institute For Cancer Research Ltd A2/ny-eso-1 specific t cell receptors and uses thereof
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
WO2023288203A2 (en) 2021-07-12 2023-01-19 Ludwig Institute For Cancer Research Ltd T cell receptors specific for tumor-associated antigens and methods of use thereof
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024067821A1 (zh) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
IL139345A0 (en) * 1998-05-19 2001-11-25 Avidex Ltd Multivalent t cell receptor complexes
DE69936927T2 (de) * 1998-10-21 2008-05-15 Altor Bioscience Corp., Miramar Polyspezifische bindemoleküle und deren verwendung
EP1287363A2 (en) * 2000-05-25 2003-03-05 Sunol Molecular Corporation Modulation of t-cell receptor interactions
AU2001275246B2 (en) * 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2003020763A2 (en) * 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US8143376B2 (en) * 2004-05-19 2012-03-27 Immunocore Limited High affinity NY-ESO T cell receptor
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
EP1763365B1 (en) * 2004-06-09 2016-08-10 Technion Research And Development Foundation, Ltd. Antibodies for selective apoptosis of cells
EP1809669A2 (en) * 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
CN101370827B (zh) * 2005-12-21 2015-10-14 麦克罗梅特股份公司 具有cea抗性的药物组合物
KR20080090441A (ko) * 2005-12-21 2008-10-08 메디뮨 엘엘씨 Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
GB0816096D0 (en) 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
LT2432802T (lt) 2017-01-10
JP5667171B2 (ja) 2015-02-12
PT3112376T (pt) 2019-05-20
US10517960B2 (en) 2019-12-31
ES2672095T3 (es) 2018-06-12
MX340168B (es) 2016-06-29
JP2017110019A (ja) 2017-06-22
PL2432802T3 (pl) 2017-07-31
AU2010250951A1 (en) 2011-12-08
MX2011012184A (es) 2012-03-26
LT3112376T (lt) 2019-05-10
PL3112377T3 (pl) 2018-10-31
TR201905437T4 (tr) 2019-05-21
EP3112377B1 (en) 2018-04-18
US20190231895A1 (en) 2019-08-01
EP3112376B1 (en) 2019-01-23
CY1121558T1 (el) 2020-05-29
HUE043245T2 (hu) 2019-08-28
US10420846B2 (en) 2019-09-24
EA201101660A1 (ru) 2012-05-30
EA201101660A8 (ru) 2014-09-30
EP3112376A2 (en) 2017-01-04
HUE032929T2 (hu) 2017-11-28
LT3112377T (lt) 2018-05-25
HRP20180757T1 (hr) 2018-07-27
HRP20190674T1 (hr) 2019-08-09
EP3112376A3 (en) 2017-03-29
ES2721058T3 (es) 2019-07-26
CY1118405T1 (el) 2017-06-28
WO2010133828A1 (en) 2010-11-25
TR201809945T4 (tr) 2018-08-27
EA020841B1 (ru) 2015-02-27
CA2968393A1 (en) 2010-11-25
GB0908613D0 (en) 2009-06-24
PL3112376T3 (pl) 2019-07-31
SI2432802T1 (sl) 2017-01-31
JP2015096527A (ja) 2015-05-21
AU2010250951B2 (en) 2015-04-30
EP3112377A1 (en) 2017-01-04
CA2968393C (en) 2019-07-23
DK3112376T3 (en) 2019-04-29
PT2432802T (pt) 2017-02-13
HRP20170086T1 (hr) 2017-06-02
JP2019172678A (ja) 2019-10-10
DK3112377T3 (en) 2018-07-30
US20190247512A1 (en) 2019-08-15
CA2762604C (en) 2018-01-16
EP2432802A1 (en) 2012-03-28
HUE038342T2 (hu) 2018-10-29
JP2012527439A (ja) 2012-11-08
US20230241238A1 (en) 2023-08-03
US20190231896A1 (en) 2019-08-01
US20190275165A1 (en) 2019-09-12
US20120190828A1 (en) 2012-07-26
ES2608653T3 (es) 2017-04-12
PT3112377T (pt) 2018-07-13
CN102439034A (zh) 2012-05-02
BRPI1013029A2 (pt) 2016-04-05
US10130721B2 (en) 2018-11-20
US10576162B2 (en) 2020-03-03
CA2762604A1 (en) 2010-11-25
EP2432802B1 (en) 2016-11-02
CN102439034B (zh) 2015-01-28
DK2432802T3 (en) 2017-02-13
SI3112376T1 (sl) 2019-08-30
SI3112377T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
CY1120439T1 (el) Διλειτουργικα πολυπεπτιδια
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
CY1124835T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1122092T1 (el) Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4
WO2018134691A3 (en) Cell surface conjugates and related cell compositions and methods
CY1111819T1 (el) Αντισωμα εναντι epcam και χρησεις αυτου
CY1117827T1 (el) Anti-ifnar1 αντισωματα me μειωμενη συγγενεια προσδετη fc
MX2012003939A (es) Fusiones y conjugados de farmaco.
MX2013014961A (es) Variantes anticuerpos y usos de las mismas.
ATE465176T1 (de) Il-7-varianten mit reduzierter immunogenität
EP2535351A3 (en) Dual specificity antibody fusions
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
MX2012009175A (es) Metodos para identificar y aislar celulas que expresan un polipeptido.
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
WO2009099777A3 (en) Chimeric hiv fusion proteins as vaccines
MX2022007404A (es) Materiales y metodos para direccionamiento biologico in vivo.
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
WO2019071009A3 (en) Lipid-based antigens and t-cell receptors on nk cells